SynAct Pharma AB

OM:SYNACT Stock Report

Market Cap: SEK 1.3b

SynAct Pharma Future Growth

Future criteria checks 5/6

SynAct Pharma is forecast to grow earnings and revenue by 111.6% and 111% per annum respectively while EPS is expected to grow by 62.6% per annum.

Key information

111.6%

Earnings growth rate

62.63%

EPS growth rate

Biotechs earnings growth38.7%
Revenue growth rate111.0%
Future return on equityn/a
Analyst coverage

Low

Last updated02 Nov 2025

Recent future growth updates

Recent updates

We're Keeping An Eye On SynAct Pharma's (STO:SYNACT) Cash Burn Rate

Sep 09
We're Keeping An Eye On SynAct Pharma's (STO:SYNACT) Cash Burn Rate

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

Sep 18
We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

Sep 04
Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

Jan 18
Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03
Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07
SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Earnings and Revenue Growth Forecasts

OM:SYNACT - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20278528N/A211
12/31/202611457N/A1622
12/31/2025N/A-113N/A-1112
9/30/2025N/A-106-91-91N/A
6/30/2025N/A-91-89-89N/A
3/31/2025N/A-82-107-107N/A
12/31/2024N/A-82-89-89N/A
9/30/2024N/A-155-92-92N/A
6/30/2024N/A-166-82-82N/A
3/31/2024N/A-191-81-81N/A
12/31/2023N/A-216-100-100N/A
9/30/2023N/A-156-102-102N/A
6/30/2023N/A-148-129-129N/A
3/31/2023N/A-129-131-131N/A
12/31/2022N/A-99-118-118N/A
9/30/2022N/A-95-116-116N/A
6/30/2022N/A-89-92-92N/A
3/31/2022N/A-78-72-72N/A
12/31/2021N/A-69-65-65N/A
9/30/2021N/A-52-56-56N/A
6/30/2021N/A-41-47-47N/A
3/31/2021N/A-35-34-34N/A
12/31/2020N/A-27-33-33N/A
9/30/2020N/A-29-32-33N/A
6/30/2020N/A-24-27-28N/A
3/31/2020N/A-23-22-22N/A
12/31/2019N/A-24-17-17N/A
9/30/2019N/A-20-12-11N/A
6/30/2019N/A-23N/A-15N/A
3/31/2019N/A-24N/A-25N/A
12/31/2018N/A-23N/A-24N/A
9/30/2018N/A-23N/A-22N/A
6/30/2018N/A-19N/A-19N/A
3/31/2018N/A-15N/A-15N/A
12/31/2017N/A-15N/A-17N/A
9/30/2017N/A-23N/A-24N/A
12/31/2016N/A-21N/A-20N/A
12/31/2015N/A-1N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYNACT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: SYNACT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SYNACT is expected to become profitable in the next 3 years.

Revenue vs Market: SYNACT's revenue (111% per year) is forecast to grow faster than the Swedish market (3.9% per year).

High Growth Revenue: SYNACT's revenue (111% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SYNACT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/27 21:51
End of Day Share Price 2025/12/23 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SynAct Pharma AB is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrik LingDNB Carnegie
Jyoti PrakashEdison Investment Research
Carl RamaniusRedeye